IL143323A0 - 2,3,4,4a-tetrahydro-1h-pyrazino (1,2-a) quinoxalin-5 (6h) one derivatives being 5ht2c agonists - Google Patents

2,3,4,4a-tetrahydro-1h-pyrazino (1,2-a) quinoxalin-5 (6h) one derivatives being 5ht2c agonists

Info

Publication number
IL143323A0
IL143323A0 IL14332399A IL14332399A IL143323A0 IL 143323 A0 IL143323 A0 IL 143323A0 IL 14332399 A IL14332399 A IL 14332399A IL 14332399 A IL14332399 A IL 14332399A IL 143323 A0 IL143323 A0 IL 143323A0
Authority
IL
Israel
Prior art keywords
pyrazino
quinoxalin
tetrahydro
derivatives
5ht2c agonists
Prior art date
Application number
IL14332399A
Other languages
English (en)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of IL143323A0 publication Critical patent/IL143323A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL14332399A 1998-12-17 1999-12-16 2,3,4,4a-tetrahydro-1h-pyrazino (1,2-a) quinoxalin-5 (6h) one derivatives being 5ht2c agonists IL143323A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21347198A 1998-12-17 1998-12-17
PCT/US1999/029894 WO2000035922A1 (en) 1998-12-17 1999-12-16 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivates being 5ht2c agonists

Publications (1)

Publication Number Publication Date
IL143323A0 true IL143323A0 (en) 2002-04-21

Family

ID=22795247

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14332399A IL143323A0 (en) 1998-12-17 1999-12-16 2,3,4,4a-tetrahydro-1h-pyrazino (1,2-a) quinoxalin-5 (6h) one derivatives being 5ht2c agonists

Country Status (18)

Country Link
EP (1) EP1140940A1 (no)
JP (1) JP2002532504A (no)
KR (1) KR20010108025A (no)
CN (1) CN1240701C (no)
AR (1) AR022687A1 (no)
AU (1) AU3123400A (no)
BR (1) BR9916326A (no)
CA (1) CA2351385A1 (no)
CZ (1) CZ20012193A3 (no)
EA (1) EA200100671A1 (no)
HU (1) HUP0104773A3 (no)
IL (1) IL143323A0 (no)
NO (1) NO20013001D0 (no)
NZ (1) NZ512765A (no)
PL (1) PL348815A1 (no)
SK (1) SK8192001A3 (no)
WO (1) WO2000035922A1 (no)
ZA (1) ZA200104598B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
WO2002010169A1 (en) * 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives
US7141563B2 (en) 2000-11-03 2006-11-28 Wyeth Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
US6916922B2 (en) 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
AR031202A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
DE60106641T2 (de) * 2000-11-03 2005-12-01 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
US6784172B2 (en) 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AU1529402A (en) 2000-11-20 2002-05-27 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
ES2260335T3 (es) * 2000-12-20 2006-11-01 Bristol-Myers Squibb Pharma Company Derivados de pirazinoquinoxalina como agonistas y antagonistas de serotonina.
WO2002051844A1 (en) 2000-12-27 2002-07-04 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
JPWO2002074746A1 (ja) * 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
DK1392292T3 (da) 2001-06-01 2006-05-29 Alcon Inc Pyranoindazoler og deres anvendelse til behandling af glaukom
EP1392269A1 (en) 2001-06-01 2004-03-03 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
JP2004532887A (ja) 2001-06-01 2004-10-28 アルコン,インコーポレイテッド 新規な融合インダゾールおよびインドールおよび緑内障治療へのこれらの使用
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
BR0311970A (pt) 2002-06-19 2005-03-29 Biovitrum Ab Novos compostos, seu uso e preparação
JP2006511556A (ja) 2002-12-13 2006-04-06 アルコン,インコーポレイテッド 新規のベンゾピラン類似体及び緑内障の治療のためのそれらの使用
AU2003303210A1 (en) 2002-12-19 2004-07-14 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
KR20060065584A (ko) * 2003-06-20 2006-06-14 아레나 파마슈티칼스, 인크. N-페닐-피페라진 유도체 및 5ht2c 수용체 관련 질환의예방 또는 치료 방법
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
NZ553848A (en) * 2004-09-30 2010-01-29 Hoffmann La Roche Benzoxazine and quinoxaline derivatives and their use in treating diseases associated with the central nervous system
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
KR101110199B1 (ko) 2009-05-18 2012-03-14 한국화학연구원 피페라진-퀴놀린 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
WO2011044134A1 (en) 2009-10-05 2011-04-14 Albany Molecular Research, Inc. Epiminocycloalkyl(b)indole derivatives as serotonin sub-type 6 (5-ht6) modulators and uses thereof
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US8492591B2 (en) 2010-02-04 2013-07-23 The Board Of Trustees Of The University Of Illinois Highly selective 5-HT(2C) receptor agonists that show anti-psychotic effects with antagonist activity at the 5-HT(2B) receptor
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
AU2012207335A1 (en) 2011-01-19 2013-07-25 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
ES2889876T3 (es) 2015-01-29 2022-01-14 Univ Illinois Ciclopropilmetanaminas como agonistas selectivos del receptor 5-HT(2C)
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
US4089958A (en) * 1976-12-20 1978-05-16 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2]quinoxalin-5(6)-ones and derivatives thereof
US4203987A (en) * 1979-05-21 1980-05-20 American Home Products Corporation 3-[Pyridinylalkyl and piperidinylalkyl]-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-ones
GB8917333D0 (en) * 1989-07-28 1989-09-13 Merck Sharp & Dohme Therapeutic agents
EP0539209A1 (en) * 1991-10-24 1993-04-28 The Upjohn Company Benzo-isoquinoline derivatives and analogs and their use in therapeutics
WO1996023789A1 (fr) * 1995-02-03 1996-08-08 Sankyo Company, Limited Derives d'hexahydropyrazinoquinoline

Also Published As

Publication number Publication date
NZ512765A (en) 2003-10-31
CN1330652A (zh) 2002-01-09
HUP0104773A2 (hu) 2002-04-29
CN1240701C (zh) 2006-02-08
EA200100671A1 (ru) 2001-12-24
BR9916326A (pt) 2001-10-02
CZ20012193A3 (cs) 2001-12-12
NO20013001L (no) 2001-06-15
AU3123400A (en) 2000-07-03
EP1140940A1 (en) 2001-10-10
ZA200104598B (en) 2002-09-05
HUP0104773A3 (en) 2004-10-28
SK8192001A3 (en) 2001-12-03
PL348815A1 (en) 2002-06-17
NO20013001D0 (no) 2001-06-15
CA2351385A1 (en) 2000-06-22
WO2000035922A1 (en) 2000-06-22
JP2002532504A (ja) 2002-10-02
KR20010108025A (ko) 2001-12-07
AR022687A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
IL143323A0 (en) 2,3,4,4a-tetrahydro-1h-pyrazino (1,2-a) quinoxalin-5 (6h) one derivatives being 5ht2c agonists
DE69941083D1 (en) 12,13-cyclopropan-epothilonderivate
HK1018439A1 (en) 5h-thiazolo (3,2-a) pyrimidine derivatives
SG71077A1 (en) 8-Substituted-1,3, 8-triaza-spiro (4.5)decan-4-on derivatives
HUP9903072A3 (en) 5,7-dihydroxy-chroman-4-on derivatives as immuno suppressive agents
ZA989230B (en) Prostaglandin agonists.
SI0921125T1 (en) 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
PL342542A1 (en) Substituted 2-phenyl-1-(3,4-diphydroxy-5-nitrophenyl)-ethanones
ZA987688B (en) 6,9-bridged erythromycin derivatives
IL127399A0 (en) 1,3,8-Triaza-spiro (4,5) decan-4-on derivatives
IL128701A0 (en) 1,2,3,4-Tetrahydro-benzofuro (3,2-c)pyridine derivatives
ZA9810920B (en) Fungicidal combinations comprising theino (2,3-d) pyrimidin-4-one
IL137792A0 (en) Alpha-methylstyrene dimer derivatives
EP1116726A4 (en) ethylamine
HUP0004317A3 (en) 5-ht1f agonists
SG83135A1 (en) Di-or triaza-spiro(4,5)decane derivatives
ZA993063B (en) 2"-deoxy hygromycin derivatives.
GB9806539D0 (en) Electroplating solution
HUP0100841A3 (en) Glycosidation of 4,5-epoxymorphinan-6-ols
GB9810998D0 (en) Antitumour 1,5-diazaanthraquinones
GB2334037B (en) Electroplating
ZA953775B (en) 8-Amino-pyrido(1,2,3-D,E)(1,3,4) Benzoxadiazine derivatives
GB2334036B (en) Electroplating
HK1018059A1 (en) Tetrahydroimidazo (2,1-A) isoquinoline derivatives.
ZA989848B (en) 6,11-bridged erythromycin derivatives